BCT197

DRUG4 trials

Sponsors

Mereo BioPharma

Conditions

Chronic Obstructive Pulmonary DiseaseInteractionPulmonary Disease, Chronic Obstructive

Phase 1

The Effect of Azithromycin on BCT197 Exposure in Healthy Male Volunteers

CompletedNCT02926326

Mereo BioPharmaInteraction

Start: 2016-09-30End: 2016-10-31Updated: 2016-10-24

The Effect of Itraconazole on BCT197 Exposure in Healthy Male Participants

CompletedNCT03498170

Mereo BioPharmaInteraction

Start: 2018-03-19End: 2018-05-09Updated: 2018-05-18

Phase 2

Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an Exacerbation

CompletedNCT01332097

Mereo BioPharmaChronic Obstructive Pulmonary Disease

Start: 2011-03-31End: 2013-05-31Updated: 2023-03-21

Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease

CompletedNCT02700919

Mereo BioPharmaPulmonary Disease, Chronic Obstructive

Start: 2016-08-01End: 2017-11-28Updated: 2020-11-30

Related Papers

Acumapimod Significantly Reduces Key Inflammatory Biomarkers in Severe COPD Exacerbations and Reduces the Rate of Re-Hospitalization

American Journal of Respiratory and Critical Care Medicine2025-05-01

Phase II Study of Single/Repeated Doses of Acumapimod (BCT197) to Treat Acute Exacerbations of COPD

COPD Journal of Chronic Obstructive Pulmonary Disease2019-11-0232 citations